Friday, October 17, 2025

Get "Stoked" About This Medical Breakthrough

Shield

AN OXFORD CLUB PUBLICATION

Loyal reader since March 2025

Wealthy Retirement

SPONSORED

Alex and Marc's New Goal: Capture the Biggest One-Year Gains in Oxford Club History.

Reserve My Spot
 

The Best Microcap Stocks Dominated the Market Last Year... Like Zivo Bioscience (Up 1,492%), Palladyne AI (Up 1,541%), and TSS Inc. (Up 3,700%).

That's Why Alexander Green and Marc Lichtenfeld Are Launching the New Microcap Magnificent Seven. The Goal: Find Tiny Stocks That Could Rise Over 1,500% in a Year. Reserve Your Spot for the Micro Mag 7 Summit Here.

Get "Stoked" About This Medical Breakthrough

Anthony Summers, Director of Trading, The Oxford Club

Anthony Summers

It's rare to find a small biotech stock that's likely standing on the edge of a medical breakthrough - but Stoke Therapeutics (Nasdaq: STOK) is one of them.

Stoke's mission is simple but bold: Use RNA science to "fix" diseases caused by missing or insufficient proteins.

The company's approach works by boosting protein production only in tissues where the protein normally exists. It doesn't alter DNA or insert new genes. Instead, it teaches the body to make more of what it's already built to make.

In August, Stoke dosed the first patient in its Phase 3 EMPEROR trial for zorevunersen, which is a potential disease-modifying treatment for Dravet syndrome - a severe form of childhood epilepsy marked by constant seizures and developmental delay. Patients will receive four doses over a 52-week period.

The main goal of the study is a reduction in seizure frequency at week 28, with secondary goals related to cognition and behavior.

Current drugs can reduce seizures but don't address the root problem. Zorevunersen might.

Early data have been encouraging. In long-term studies, patients on zorevunersen showed substantial seizure reductions and lasting improvements in cognition and behavior - signs that the treatment may truly modify the disease, not just mask it.

Results through 36 months have shown continued seizure reduction and steady gains in daily living, communication, and motor skills.

Beyond zorevunersen, Stoke is advancing another treatment called STK-002 for autosomal dominant optic atrophy (ADOA). Management confirmed that STK-002 has begun a Phase 1 study in the U.K. The company is also exploring other disorders such as SYNGAP1, expanding its reach across rare neurological conditions.

Now, the Value Meter test.

Value Meter Analysis: Stoke Therapeutics (Nasdaq: STOK)
View larger image
 

On valuation, EV/NAV stands at 2.13, about half the peer average of 4.20. Investors are paying less for Stoke's assets than for similar companies, leaving room for upside if zorevunersen succeeds.

On cash efficiency, FCF/NAV averages -2.69%, compared with a peer average of 0.79%. That's normal for a clinical-stage biotech. It signals steady spending, not waste.

On consistency, Stoke's 12-quarter FCF growth rate of 45.5% nearly matches the peer average of 46.2%. For a company still in the clinic, that's a quiet sign of control.

(The company expects its current cash to fund operations through mid-2028, helped by its collaboration with Biogen, which will handle commercialization outside the U.S., Canada, and Mexico.)

Together, these numbers reveal that the market is giving Stoke credit for the science and its strong balance sheet while still pricing in the risk of a binary trial outcome.

The stock reflects that balance. It built a long base over the past year, then broke higher into the fall. Shares recently traded in the high $30s after a strong run.

Chart: Stoke Therapeutics (Nasdaq: STOK)
View larger image
 

With Phase 3 now underway and results years away, volatility will remain part of the ride.

But what does all of this mean for us now?

Get the Verdict Here

SPONSORED

Trump's Favorite AI Energy Stock??

Gears turning for natural gas
 

It's wildly profitable - Over $3 billion in operating income. It has a partnership with the hottest AI stock on Wall Street.

And Trump has publicly backed it? Get the details on #1 AI energy stock here.

This

Major Gold Announcement Imminent. Don't Miss This Opportunity!

The "Super AI" Forecasting System That Could Quadruple Your Gains

Marc Lichtenfeld Reveals Strange "23 Enigma"

This 40% Biotech Trade Works Like Clockwork

SPONSORED

AI's NEXT Magnificent Seven

Original Magnificent Seven
 

The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.

But the Man Who Called Nvidia at $1.10 Says "AI's Next Magnificent Seven Could Do It Even Faster."

See His Breakdown of the Seven Stocks You Should Own Here.

Must Read: The Next Big Move in America’s Rare Earth Revolution

Trilogy Metals soars 200% thanks to Washington – and Wall Street wants in on the action.

Undervalued Nasdaq Stocks Under $5

Investment News Daily

Welcome! Your 6 Most Active Stocks Report is Enclosed...

Information, charts or examples contained in this email are for illustration and educational purposes only and not for individualized investment management. This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. If you wish to no longer receive these offers click on the unsubscribe link at the bottom of this email. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only.We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained in this email or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

 

Copyright © TraderElite.club | Musth
20 De Boers Dr., Toronto, ON M3J 0H1, Unit # 339 | 
Unsubscribe Here

"Biggest technological buildout in world history"

Trade of the Day Logo

"Biggest Technological Buildout in World History"

Ryan Fitzwater, Publisher, Monument Traders Alliance

Ryan Fitzwater

Dear Reader,

There is something big brewing in Washington D.C.

On October 27, two major events are being held.

All the major agencies will be there.

The Departments of Defense, Energy, Transportation, Homeland Security, Agriculture, Health... all of them.

And they'll be joined by 26 major AI companies.

Their purpose?

To implement a radical new action plan released by The White House.

Trillions of dollars will be spent.

As The Oxford Club's Chief Investment Strategist Alexander Green says, "these events will lead to the biggest technological buildout in history."

The stock market will surely see dozens of dramatic moves for the stocks involved.

In fact, Alex and The Oxford Club's Chief Income Strategist, Marc Lichtenfeld, are suggesting we'll see moves as big as 1,500% in the next year for certain small stocks.

This is a very big moment for investors.

That's why we're inviting you to their special "get ready" event on October 22 at 1 p.m. ET.

You need to understand what's coming on October 27.

Every investor should.

It's free to attend. Just claim your ticket right here.

Yours in smart speculation,

Ryan Fitzwater Signature

Ryan Fitzwater, Publisher
Monument Traders Alliance

 

Page List

Blog Archive

Search This Blog

The Next Big Collapse in America: 10X Bigger than Lehman?

I just found Just Found a HUGE Red Flag for AI Stocks… ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏...